Stock-Based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Cost of goods sold	$	744	$	1,119	$	2,168	$	3,208
Research and development	14,212		15,680		43,826		47,549
General and administrative	8,711		8,081		25,255		24,030
Impairment of assets and other costs for terminated program	—		—		1,025		—
Total stock-based compensation	$	23,667	$	24,880	$	72,274	$	74,787

The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we accounted for as a liability award. Upon issuance of the award in the three months ended June 30, 2020, we reclassified the award into equity.

We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Options granted	233		131		282		246
Weighted-average grant-date fair value of options granted	$	11.64	$	13.43	$	11.68	$	15.81
RSUs granted	693		316		1,213		712
Weighted-average grant-date fair value of RSUs granted	$	21.56	$	28.00	$	21.04	$	31.80
Shares issued under equity compensation plans	584		820		2,889		2,256

On June 17, 2020, the Stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,000,000 shares, and an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by 1,000,000 shares.